Clinical trial · no report yet · Phase 3
ALTA-1L
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
- NCT02737501 ↗
- Completed
- Ariad Pharmaceuticals
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 14 | |
| YouTube | 11 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
- Interventions
- Brigatinib; Crizotinib
- Arms
- Randomized Phase: Brigatinib 90 mg QD/180 QD · Experimental
- Randomized Phase: Crizotinib 250 mg BID · Active comparator
- Crossover Phase: Brigatinib 90 mg QD/180 mg QD · Experimental
- Enrollment
- 275
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Ariad Pharmaceuticals
- Start
- May 26, 2016
- Primary completion
- Jul 28, 2020
- Results posted
- Yes
- Registry record
- NCT02737501 · updated Aug 20, 2021
Publications
linked from the registry- Al Tawil A, Lauseker M, Mansmann U. Estimating causal effects on quality of life under treatment discontinuation: the ALTA-1L trial. J Clin Epidemiol. 2026 May;193:112189. doi: 10.1016/j.jclinepi.2026.112189. Epub 2026 Feb 23. PubMed 41740899
- Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG. Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. Future Oncol. 2025 Dec;21(30):3935-3945. doi: 10.1080/14796694.2025.2592527. Epub 2025 Dec 18. PubMed 41410381
- Al Tawil A, McGrath S, Ristl R, Mansmann U. Addressing treatment switching in the ALTA-1L trial with g-methods: exploring the impact of model specification. BMC Med Res Methodol. 2024 Dec 20;24(1):314. doi: 10.1186/s12874-024-02437-6. PubMed 39707229
- Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11. PubMed 32780660
- Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25. PubMed 30280657
- Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 Jul 1;390(10089):3-4. doi: 10.1016/S0140-6736(17)31074-7. Epub 2017 May 10. No abstract available. PubMed 28501139